Cytokines in primary headache disorders: a systematic review and meta-analysis

被引:37
作者
Musubire, Abdu Kisekka [1 ,2 ,3 ]
Cheema, Sanjay [1 ,4 ]
Ray, Jason C. [5 ,6 ,7 ]
Hutton, Elspeth J. [5 ,6 ]
Matharu, Manjit [1 ,4 ]
机构
[1] Univ Coll London UCL, Queen Sq Inst Neurol, London, England
[2] Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala, Uganda
[3] Kiruddu Natl Referral Hosp, Kampala, Uganda
[4] Natl Hosp Neurol & Neurosurg, Queen Sq, London, England
[5] Alfred Hlth, Dept Neurol, Melbourne, Australia
[6] Monash Univ, Dept Neurosci, Melbourne, Australia
[7] Austin Hlth, Dept Neurol, Melbourne, Australia
关键词
Migraine disorders; Tension-type headache; Cytokine; Neurogenic inflammation; Immunology; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; TENSION-TYPE HEADACHE; GENE-RELATED PEPTIDE; SERUM-LEVELS; MIGRAINE PATIENTS; PLASMA CYTOKINES; NITRIC-OXIDE; TNF-ALPHA; BLOOD;
D O I
10.1186/s10194-023-01572-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundThe role of inflammation and cytokines in the pathophysiology of primary headache disorders is uncertain. We performed a systematic review and meta-analysis to synthesise the results of studies comparing peripheral blood cytokine levels between patients with migraine, tension-type headache, cluster headache, or new daily persistent headache (NDPH), and healthy controls; and in migraine between the ictal and interictal stages.MethodsWe searched PubMed/Medline and Embase from inception until July 2022. We included original research studies which measured unstimulated levels of any cytokines in peripheral blood using enzyme-linked immunosorbent assay or similar assay. We assessed risk of bias using the Newcastle-Ottawa Quality Assessment Scale. We used random effects meta-analysis with inverse variance weighted average to calculate standardised mean difference (SMD), 95% confidence intervals, and heterogeneity for each comparison. This study is registered with PROSPERO (registration number CRD42023393363). No funding was received for this study.ResultsThirty-eight studies, including 1335 patients with migraine (32 studies), 302 with tension-type headache (nine studies), 42 with cluster headache (two studies), and 1225 healthy controls met inclusion criteria.Meta-analysis showed significantly higher interleukin (IL)-6 (SMD 1.07, 95% CI 0.40-1.73, p = 0.002), tumour necrosis factor (TNF)-alpha (SMD 0.61, 95% CI 0.14-1.09, p = 0.01), and IL-8 (SMD 1.56, 95% CI 0.03-3.09, p = 0.04), in patients with migraine compared to healthy controls, and significantly higher interleukin-1 beta (IL-1 beta) (SMD 0.34, 95% CI 0.06-0.62, p = 0.02) during the ictal phase of migraine compared to the interictal phase. Transforming growth factor (TGF)-beta (SMD 0.52, 95% CI 0.18-0.86, p = 0.003) and TNF-alpha (SMD 0.64, 95% CI 0.33-0.96, p = 0.0001) were both higher in patients with tension-type headache than controls.ConclusionsThe higher levels of the proinflammatory cytokines IL-6, IL-8 and TNF-alpha in migraine compared to controls, and IL-1 beta during the ictal stage, suggest a role for inflammation in the pathophysiology of migraine, however prospective studies are required to confirm causality and investigate the mechanisms for the increase in cytokine levels identified. Cytokines may also have a role in tension-type headache. Due a lack of data, no conclusions can be made regarding cluster headache or NDPH.
引用
收藏
页数:12
相关论文
共 78 条
[11]   INCREASED SPONTANEOUS RELEASE OF TUMOR-NECROSIS-FACTOR-ALPHA CACHECTIN IN HEADACHE PATIENTS - A POSSIBLE CORRELATION WITH PLASMA ENDOTOXIN AND HYPOTHALAMIC-PITUITARY-ADRENAL AXIS [J].
COVELLI, V ;
MASSARI, F ;
FALLACARA, C ;
MUNNO, I ;
PELLEGRINO, NM ;
JIRILLO, E ;
SAVASTANO, S ;
GHIGGI, MR ;
TOMMASELLI, AP ;
LOMBARDI, G .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1991, 61 (1-2) :53-60
[12]   Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen [J].
Cowan, Robert P. ;
Gross, Noah B. ;
Sweeney, Melanie D. ;
Sagare, Abhay P. ;
Montagne, Axel ;
Arakaki, Xianghong ;
Fonteh, Alfred N. ;
Zlokovic, Berislav, V ;
Pogoda, Janice M. ;
Harrington, Michael G. .
HEADACHE, 2021, 61 (03) :536-545
[13]   Substance P and calcitonin gene-related peptide increase IL-1β, IL-6 and TNFα secretion from human peripheral blood mononuclear cells [J].
Cuesta, MC ;
Quintero, L ;
Pons, H ;
Suarez-Roca, H .
NEUROCHEMISTRY INTERNATIONAL, 2002, 40 (04) :301-306
[14]   Clinical Value of Serum Neuroplasticity Mediators in Identifying the Central Sensitivity Syndrome in Patients With Chronic Pain With and Without Structural Pathology [J].
Deitos, Alicia ;
Dussan-Sarria, Jairo A. ;
de Souza, Andressa ;
Medeiros, Liciane ;
Tarrago, Maria da Graca ;
Sehn, Francislea ;
Chassot, Monica ;
Zanette, Simone ;
Schwertner, Andre ;
Fregni, Felipe ;
Torres, Iraci L. S. ;
Caumo, Wolnei .
CLINICAL JOURNAL OF PAIN, 2015, 31 (11) :959-967
[15]  
Della Vedova C, 2013, PAIN RES MANAG, V18, P301
[16]   Increased serum levels of interleukin-8 in patients with tension-type headache [J].
Domingues, Renan B. ;
Duarte, Halina ;
Rocha, Natalia P. ;
Teixeira, Antonio L. .
CEPHALALGIA, 2015, 35 (09) :801-806
[17]   CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study [J].
Dominguez, Clara ;
Vieites-Prado, Alba ;
Perez-Mato, Maria ;
Sobrino, Tomas ;
Rodriguez-Osorio, Xiana ;
Lopez, Ana ;
Campos, Francisco ;
Martinez, Francisco ;
Castillo, Jose ;
Leira, Rogelio .
HEADACHE, 2018, 58 (01) :78-87
[18]   Investigation of serum vaspin, visfatin, chemerin and IL-18 levels in migraine patients [J].
Donder, Ahmet ;
Cafer, Vugar ;
Yilmaz, Ahmet ;
Aslanhan, Hamza ;
Arikanoglu, Adalet .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (09) :789-794
[19]   Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine [J].
Duarte, Halina ;
Teixeira, Antonio L. ;
Rocha, Natalia P. ;
Domingues, Renan B. .
NEUROLOGICAL SCIENCES, 2015, 36 (02) :203-208
[20]   Understanding the symptoms of the common cold and influenza [J].
Eccles, R .
LANCET INFECTIOUS DISEASES, 2005, 5 (11) :718-725